25周年を記念 1999-2024
*3年間で¥ 153396、たったの¥ 61358
フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Expects to Deliver Another Year of Double-Digit EPS Growth ABBOTT PARK, Ill., Jan. 12 /PRNewswire-FirstCall/ -- Abbott today is announcing its...
ABBOTT PARK, Ill., Dec. 18 /PRNewswire-FirstCall/ -- Abbott will announce its financial results for the fourth-quarter and full year ended Dec...
ABBOTT PARK, Ill., Dec. 16 /PRNewswire-FirstCall/ -- Abbott will present at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan...
Superhero Costume Contest, Grants for Families and Honors for Corporate Support in Fighting Childhood Cancer and Assisting Families Affected...
ABBOTT PARK, Ill., Oct. 20 /PRNewswire-FirstCall/ -- Abbott has received a Complete Response Letter from the U.S. Food and Drug Administration...
New Resources and ADA Feria Events During Hispanic Heritage Month Work to Combat Diabetes in the Hispanic/Latino American Population ALEXANDRIA...
Joint Effort with Baylor International Pediatric AIDS Initiative Will Improve Access to Health Care for Children with HIV/AIDS WASHINGTON, Aug...
WASHINGTON, July 30 /PRNewswire-FirstCall/ -- Abbott today announced the recipients of the Labs Are Vital(TM) instrument donation program today...
Study Highlights Performance of Abbott's ARCHITECT Tacrolimus Assay, Only Automated Transplant Monitoring Test that Meets International Standards...
Data Presented at American Association for Clinical Chemistry (AACC) Meeting Show Urine NGAL Can Potentially Save Lives by Enabling Faster...
XIENCE V USA Study to Evaluate Treatment of Coronary Artery Disease Patients in Real-World Setting ABBOTT PARK, Ill., July 9...
XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for...
More Than Half of Teens Who Report Abusing Prescription Medications Get Them from Their Own Home, a Parent, Relative or Friend NEW YORK, June 24...
PARIS, June 13 /PRNewswire-FirstCall/ -- Seven-year rheumatoid arthritis (RA) data from open-label extension studies show that treatment with...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約